Cystatin C and long term risk of community-acquired sepsis: A population-based cohort study Epidemiology and Health Outcomes

BMC Nephrology

Volumn 16, Issue 1, 2015, Pages

  Powell, Thomas Clark ^a   Donnelly, John P ^a,b   Gutiérrez, Orlando M ^a,b   Griffin, Russell L ^b   Safford, Monika M ^a   Wang, Henry E ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Biomarkers; Cystatin C; Epidemiology; Sepsis

Indexed keywords

CYSTATIN C; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; CST3 PROTEIN, HUMAN; SERUM ALBUMIN;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; BRONCHITIS; CATHETER INFECTION; COHORT ANALYSIS; COMMUNITY ACQUIRED INFECTION; COMMUNITY ACQUIRED SEPSIS; FEMALE; HEALTH BEHAVIOR; HOSPITALIZATION; HUMAN; INFLUENZA; KIDNEY INFECTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MIDDLE AGED; OUTCOME ASSESSMENT; PNEUMONIA; PROTEIN BLOOD LEVEL; PYREXIA IDIOPATHICA; RISK FACTOR; SKIN INFECTION; SOFT TISSUE INFECTION; SURGICAL WOUND; URINARY TRACT INFECTION; CHRONIC KIDNEY FAILURE; COMMUNITY-ACQUIRED INFECTIONS; GLOMERULUS FILTRATION RATE; INFLAMMATION; LONGITUDINAL STUDY; METABOLISM; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SEPSIS; URINARY TRACT INFECTIONS;

AGED; BIOMARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; CREATININE; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PNEUMONIA; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SEPSIS; SERUM ALBUMIN; URINARY TRACT INFECTIONS;

EID: 84928996132     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-015-0055-z     Document Type: Article

References (38)

1. Wang HE, Shapiro NI, Angus DC, Yealy DM. National estimates of severe sepsis in United States emergency departments. Crit Care Med. 2007;35(8):1928-36.
2. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-10.
4. Yende S, Angus DC, Ali IS, Somes G, Newman AB, Bauer D, et al. Influence of comorbid conditions on long-term mortality after pneumonia in older people. J Am Geriatr Soc. 2007;55(4):518-25.
5. Ojard C, Donnelly J, Safford M, Griffin R, Wang H. 632: depression and risk of sepsis. Crit Care Med. 2013;41(12):A155. Doi:110.1097/1001.ccm.0000439872.0000456454.0000439878e.
6. Powell TC, Powell SL, Allen BK, Griffin RL, Warnock DG, Wang HE. Association of inflammatory and endothelial cell activation biomarkers with acute kidney injury after sepsis. SpringerPlus. 2014;3:207.
7. Wang HE, Baddley J, Griffin RL, Judd S, Howard G, Donnelly JP, et al. Physical inactivity and long-term rates of community-acquired sepsis. Prev Med. 2014;65:58-64.
8. Wang HE, Griffin R, Judd S, Shapiro NI, Safford MM. Obesity and risk of sepsis: A population-based cohort study. Obesity (Silver Spring). 2013 Dec;21(12):E762-9.
9. Wang HE, Shapiro NI, Griffin R, Safford MM, Judd S, Howard G. Chronic medical conditions and risk of sepsis. PLoS One. 2012;7(10):e48307.
10. Wang HE, Shapiro NI, Griffin R, Safford MM, Judd S, Howard G. Inflammatory and endothelial activation biomarkers and risk of sepsis: A nested case-control study. Journal of critical care. 2013 Oct;28(5):549-55.
11. Wang HE, Shapiro NI, Safford MM, Griffin R, Judd S, Rodgers JB, et al. High-sensitivity C-reactive protein and risk of sepsis. PLoS One. 2013;8(7):e69232.
12. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci. 2004;41(5-6):467-550.
13. Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA. 2011;305(15):1545-52.
14. Shlipak MG, Matsushita K, Ärnlöv J, Inker LA, Katz R, Polkinghorne KR, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369(10):932-43.
15. Salgado JV, Souza FL, Salgado BJ. How to understand the association between cystatin C levels and cardiovascular disease: Imbalance, counterbalance, or consequence? J Cardiol. 2013;62(6):331-5.
16. Evangelopoulos AA, Vallianou NG, Bountziouka V, Katsagoni C, Bathrellou E, Vogiatzakis ED, et al. Association between serum cystatin C, monocytes and other inflammatory markers. Intern Med J. 2012;42(5):517-22.
17. Zhang Z, Lu B, Sheng X, Jin N. Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis. Am J Kidney Dis. 2011;58(3):356-65.
18. Salgado JV, Franca AK, Cabral NA, Lages J, Ribeiro VS, Santos AM, et al. Cystatin C, kidney function, and cardiovascular risk factors in primary hypertension. Rev Assoc Med Bras (1992). 2013;59(1):21-7.
19. Okura T, Jotoku M, Irita J, Enomoto D, Nagao T, Desilva VR, et al. Association between cystatin C and inflammation in patients with essential hypertension. Clin Exp Nephrol. 2010;14(6):584-8.
20. Lertnawapan R, Bian A, Rho YH, Kawai VK, Raggi P, Oeser A, et al. Cystatin C, renal function, and atherosclerosis in rheumatoid arthritis. J Rheol. 2011;38(11):2297-300.
21. Lertnawapan R, Bian A, Rho YH, Raggi P, Oeser A, Solus JF, et al. Cystatin C is associated with inflammation but not atherosclerosis in systemic lupus erythematosus. Lupus. 2012;21(3):279-87.
22. Nakai K, Kikuchi M, Fujimoto K, Kaneko Y, Omori S, Nakai K, et al. Serum levels of cystatin C in patients with malignancy. Clin Exp Nephrol. 2008;12(2):132-9.
23. Demirtas S, Akan O, Can M, Elmali E, Akan H. Cystatin C can be affected by nonrenal factors: a preliminary study on leukemia. Clin Biochem. 2006;39(2):115-8.
24. Choudhury D, Luna-Salazar C. Preventive health care in chronic kidney disease and end-stage renal disease. Nat Clin Pract Nephrol. 2008;4(4):194-206.
25. Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest. 2001;120(6):1883-7.
26. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2000;58(4):1758-64.
27. Viasus D, Garcia-Vidal C, Cruzado JM, Adamuz J, Verdaguer R, Manresa F, et al. Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. Nephrol Dial Transplant. 2011;26(9):2899-906.
28. Nejat M, Pickering JW, Walker RJ, Westhuyzen J, Shaw GM, Frampton CM, et al. Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit. Crit Care. 2010;14(3):R85.
29. Dalrymple LS, Katz R, Kestenbaum B, de Boer IH, Fried L, Sarnak MJ, et al. The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis. 2012;59(3):356-63.
30. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology. 2005;25(3):135-43.
31. Willenbring ML, Massey SH, Gardner MB. Helping patients who drink too much: an evidence-based guide for primary care clinicians. Am Fam Physician. 2009;80(1):44-50.
32. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.
33. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959-65.
34. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med. 1991;10(4):585-98.
35. Rubin DB. Multiple imputation after 18+ years. J Am Stat Assoc. 1996;91(434):473-89.
36. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65(4):1416-21.
37. Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75(6):652-60.
38. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev. 2007;65(12 Pt 2):S253-9.